Evolva Holding S.A.
ELVAY
Other OTC1.16
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christian Wichert
- Full Time Employees
- 50
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Duggingerstrasse 23 Reinach Switzerland 4153
- IPO Date
- Feb 4, 2014
- Website
- evolva.com
- Similar Companies
- Business
- Evolva Holding SA is a Swiss holding company formerly engaged in researching, developing, and commercializing nature-based ingredients primarily for the flavor and fragrance, health ingredients, and health protection markets. Its core product portfolio included Veri-te Resveratrol, a nature-derived polyphenol sourced from grapes and other plants; L-Arabinose, a flavoring agent used in Maillard reactions; Valencene, a citrus aroma compound; Nootkatone, a grapefruit aroma ingredient produced via biochemical oxidation of valencene; and Vanillin, derived from vanilla beans. These products were manufactured through biotechnology and fermentation processes and marketed worldwide with key operations in Switzerland, the United States, and several other international markets. In a significant strategic shift completed in December 2023, Evolva sold its main operating subsidiary, Evolva AG, to a subsidiary of Lallemand Inc., which marked the company's exit from active ingredient operations. Following the divestment, Evolva transitioned into a holding company managing its remaining assets and financial interests. Additionally, in mid-2025, the company initiated a name change to EvoNext Holdings SA to reflect its new focus as a holding and investment entity. Evolva has also been engaged in expanding its distribution partnerships for its Veri-te Resveratrol product in Europe and Asia and has pursued strategic financing arrangements amid ongoing business transformations. Founded in 2004 and headquartered in Reinach, Switzerland, Evolva operated within the biotechnology industry before the divestiture, targeting customers in the flavor and fragrance, nutrition, and health sectors with its high-purity, nature-based ingredients. The company has since shifted its focus away from direct product manufacturing and commercialization toward asset management and strategic corporate initiatives following the sale of its operating business. This repositioning signifies a major operational and strategic realignment in Evolva's corporate profile and market activities.